FDA slaps myocarditis warning on Pfizer vax
The TGA is investigating Australian reports of the adverse event as well as reports of Guillain-Barre syndrome following inoculation with AstraZeneca’s vaccine
The US medicines regulator has updated the product information for Pfizer’s COVID-19 vaccine to include warnings about the potential risk of myocarditis and pericarditis.
The FDA warning issued last week followed increasing rates of the rare adverse event among young patients receiving Pfizer or Moderna mRNA vaccines, particularly after the second dose.
